+++
A. Health Maintenance: Across the Ages What Not to Do
++
Conditions for which the USPSTF recommends against routine screening in asymptomatic adults:
++
Aspirin to prevent myocardial infarction in men aged <45 years
Asymptomatic bacteriuria in men and nonpregnant women
Bacterial vaginosis in asymptomatic pregnant women at low risk for preterm delivery
BRCA-related cancers in women not at increased risk
Cancers: cervix (if hysterectomy), ovary, pancreas, prostate, testicular
Carotid artery stenosis
Chronic obstructive pulmonary disease
Electrocardiography (ECG)
Genital herpes
Gonorrhea in low-risk men and women
Heart disease in low-risk patients using ECG, electron-beam computed tomography (EBCT)
Hemochromatosis
Hepatitis B
Routine aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) for primary prevention of colorectal cancer for average risk
Scoliosis
Stress echocardiogram
Syphilis
++
Vitamin supplements with β-carotene to prevent cancer and cardiovascular disease (CVD)
+++
B. Health Maintenance: Across the Ages—Insufficient Evidence
++
Conditions for which the USPSTF found insufficient evidence to promote routine screening in asymptomatic adults at low risk:
++
Abuse of elderly and vulnerable adults
Cancers: bladder, oral, skin
Chlamydia in men
Clinical breast examination beyond screening mammography, women aged ≥40 years
Dementia
Diabetes mellitus if blood pressure (BP) <135/80 mmHg
Drug abuse
Family violence
Gestational diabetes mellitus
Glaucoma
Lung cancer
Peripheral artery disease with the ankle-brachial index
Suicide risk
Thyroid disease
Vitamin supplementation with A, C, E, multivitamins to prevent cancer and heart disease
Vitamin D and calcium supplementation to prevent fractures: men, premenopausal women
+++
C. Health Maintenance: Across the Ages—Aspirin
++
The role of aspirin in health maintenance and promotion varies according to whether it is used for primary or secondary/tertiary prevention. For the latter, it is generally beneficial (Table 15-3). For primary prevention it is not that simple (Tables 15-4, 15-5, and 15-6). The USPSTF recommends against the routine use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent colorectal cancer in persons at average risk for colorectal cancer (grade D recommendation).
++
++
++
++
++
+++
D. Health Maintenance: Ages 18–39
++
Table 15-7 summarizes USPSTF grade A and grade B screening and counseling recommendations for average-risk 18–39-year-olds. Below the screening tests in focus are as follows: hypertension, cervical cancer, Chlamydia, lipid disorders, depression, tobacco, and specific screening for those at increased risk.
++
++
Hypertension is the most common condition seen in family medicine. It contributes to many adverse health outcomes, including premature deaths, heart attacks, renal insufficiency, and stroke. Blood pressure measurement identifies individuals at increased risk for cardiovascular disease. Treatment of hypertension decreases the incidence of cardiovascular disease events.
++
Hypertension is defined as elevated blood pressure, either systolic blood pressure (SBP) or diastolic blood pressure (DBP), on at least two separate occasions separated by one to several weeks. In persons
++
18–60 years of age—elevation is either a SBP of ≥140 mmHg or a DBP of ≥90 mmHg.
≥60 years of age—elevation is either a SBP of ≥150 mmHg or a DBP of ≥90 mmHg.
≥18 years of age with chronic kidney disease—defined as an estimated or measured glomerular filtration rate of <60 mL/min per 1.73 m2 in individuals aged <70 years–elevation is either a SBP of ≥140 mmHg or a DBP of ≥90 mmHg.
Of any age with albuminuria (>30 mg of albumin/g of creatinine)—elevation is either a SBP of ≥140 mmHg or a DBP of ≥90 mmHg.
++
The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC8) recommends screening every 2 years in persons with blood pressure of <120/80 mmHg and every year with systolic blood pressure of 120–139 mmHg or diastolic blood pressure of 80–90 mmHg. The American Heart Association (AHA) has issued similar recommendations beginning at age 20.
++
Hypertension should be treated. Treatment is addressed in Chapter 35.
++
Cervical cancer screening is discussed in detail in Chapter 27.
+++
3. Chlamydia screening
++
The USPSTF recommends screening for Chlamydia infection in all sexually active women aged ≤24 years, or women aged ≥25 years at increased risk. The optimal screening interval for nonpregnant women is unknown. The CDC recommends at least annual screening for women at increased risk. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection in the United States. In women, genital infection may result in urethritis, cervicitis, pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and chronic pelvic pain. Infection during pregnancy is related to adverse pregnancy outcomes, including miscarriage, premature rupture of membranes, preterm labor, low birth weight, and infant mortality. The benefits of screening and subsequent treatment in high-risk pregnant and nonpregnant individuals are substantial.
++
The USPSTF identified no evidence of the benefits of screening women who are not at increased risk for Chlamydia infection. In this low-risk population it is moderately certain that the benefits outweigh the risks of screening to only a small degree. Nucleic acid amplification tests (NAATs) for Chlamydia have high specificity and sensitivity as screening tests and may be used with either urine or vaginal swabs.
++
Screening of pregnant women for Chlamydia infection is recommended for all women at the first prenatal visit. For those who remain at increased risk or acquire a new risk factor, such as a new sexual partner, screening should be repeated during the third trimester.
++
Men aged >35 years should be screened for lipid disorders. This age may be reduced to 20 if there is an increased risk for coronary heart disease. Screening for women does not need to start until age 45.
++
The optimal interval for screening is uncertain. Reasonable options include every 5 years, with shorter intervals for those with risk factors (eg, diabetes mellitus) or lipid levels close to those warranting therapy.
++
High levels of total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) and low levels of high- density lipoprotein–cholesterol (HDL-C) are independent risk factors for coronary heart disease. The risk is highest in those with a combination of risk factors. Therefore, a careful review of the complete risk factor profile is necessary to assess the benefit of screening and subsequent lowering of high cholesterol levels with medications. (Please see Chapter 37 for a full discussion of lipid disorders.)
+++
5. Depression screening
++
Depression is common and a leading cause of disability in both adolescents and adults. Screening for depression improves the accurate identification of depressed patients in primary care settings. The USPSTF concluded that the net benefit of screening adults for depression is higher (moderate) when staff-assisted depression care supports are in place to ensure accurate diagnosis, effective treatment, and follow-up. In the absence of such care supports, the net benefit may be small. Numerous formal screening tools are available, but there is insufficient evidence to recommend one tool over another. All positive screens should trigger a full diagnostic interview.
+++
6. Tobacco use counseling
++
Cessation of tobacco use may be the single most important lifestyle intervention for the maintenance and improvement of health. All adults should be assessed for tobacco use and tobacco cessation interventions provided for those who use tobacco products. Tobacco use, cigarette smoking in particular, is the leading cause of preventable death in the United States, resulting in >400,000 deaths annually from cardiovascular disease, respiratory disease, and cancer. Smoking during pregnancy results in the deaths of approximately 1000 infants annually and is associated with an increased risk for premature birth and intrauterine growth retardation. Environmental tobacco smoke may contribute to death in ≤38,000 people annually.
++
Cessation of tobacco use is associated with a corresponding reduction in the risk of heart disease, stroke, and lung disease. Tobacco cessation at any point during pregnancy yields substantial health benefits for the expectant mother and fetus.
++
Smoking cessation interventions, including brief (<10 minutes) behavioral counseling sessions and pharmacotherapy delivered in primary care settings, are effective in increasing the proportion of smokers who successfully quit and remain abstinent for 1 year. Even minimal counseling interventions (<3 minutes) are associated with improved smoking cessation rates. One of several screening strategies aimed at engaging patients in smoking cessation discussions is the “5A” behavioral counseling framework:
++
Ask about tobacco use.
Advise to quit through clear personalized messages.
Assess willingness to quit.
Assist to quit.
Arrange follow-up and support.
+++
7. Screening and counseling specifically for persons aged 18–39 years at increased risk
++
HIV—screen once for all persons aged 15–65 years, more for those at increased risk (A).
Syphilis—screen for men and women at increased risk (A).
BRCA mutation testing for breast and ovarian cancer (B).
Gonorrhea—screen women who are pregnant or at increased risk (B).
Healthy diet—screen adults with hyperlipidemia and other risk factors for coronary heart disease (CHD) (B).
Intimate-partner violence—screen women of childbearing age (B).
Sexually transmitted infections—provide behavioral counseling for sexually active adolescents and adults at increased risk (B).
Skin cancer—provide behavioral counseling for children, adolescents, and young adults aged 18–24 years (B).
Type 2 diabetes mellitus—screen men and women with sustained blood pressure of ≥135/80 mmHg (B).
Lipid disorders in adults—screen women aged 20–44 and men aged 20-34 years at increased risk for CHD (B).
+++
E. Health Maintenance: Ages 40–49 with Emphasis on Breast Cancer and Lipid Screening
++
Tables 15-8, 15-9, and 15-10 summarize USPSTF recommendations for average-risk 40–49-year-olds.
++
++
++
++
Please see Tables 15-9 and 15-10 and Chapter 27 for discussion of screening for breast cancer.
++
All women aged ≥45 years should be screened for lipid disorders. Women aged 20–44 years should be screened if they are at increased risk for coronary heart disease (CHD). Increased risk, for this recommendation, is defined by the presence of any of the following risk factors: diabetes, previous personal history of CHD or noncoronary atherosclerosis (eg, abdominal aorta aneurysm, peripheral artery disease, carotid artery stenosis), a family history of cardiovascular disease before age 50 years in male relatives or age 60 years in female relatives, tobacco use, hypertension, obesity (BMI >30). (Further discussion of dyslipidemia is found in section on health maintenance for ages 18–39 years (above) and in Chapter XX.)
+++
F. Health Maintenance: Ages 50–59
++
Table 15-11 summarizes USPSTF recommendations for average-risk 50–59-year-olds, with major changes in recommendations for prostate and lung cancer screening.
++
+++
1. Colorectal cancer screening
++
This should occur from age 50 to 75 years using a variety of tests, as follows:
++
Sensitivity—Hemoccult II < fecal immunochemical tests < Hemoccult SENSA ≈ flexible sigmoidoscopy < colonoscopy
Specificity—Hemoccult SENSA < fecal immunochemical tests ≈ Hemoccult II < flexible sigmoidoscopy = colonoscopy
++
Screening with fecal occult blood testing, sigmoidoscopy, or colonoscopy reduces mortality, assuming 100% adherence to any of these regimens: (1) annual high-sensitivity fecal occult blood testing, (2) sigmoidoscopy every 5 years combined with high-sensitivity fecal occult blood testing every 3 years, or (3) screening colonoscopy at intervals of 10 years. Evidence is insufficient regarding screening with fecal DNA or CT colonography.
++
For a more complete discussion of colorectal cancer screening, see Chapter XX.
++
Screen every 2 years if blood pressure is <120/80 mmHg and every year with systolic blood pressure of 120–139 mmHg or diastolic blood pressure of 80–90 mmHg.
++
Benefits must outweigh risks. See earlier discussion of acetylsalicylic acid (ASA) and Tables 15-3, 15-4, 15-5, and 15-6. Aspirin should not be initiated to prevent stroke in women aged <55 years of age. Aspirin should not be used to prevent colorectal cancer in persons at average risk for colorectal cancer.
+++
4. Prostate cancer screening (USPSTF recommendation D)
++
As discussed earlier, an effective screening test should detect disease early, and early treatment should improve morbidity and mortality. There is no conclusive evidence that treatment of prostate cancers detected by screening improves outcomes. Recognition of the fact that most men with prostate cancer do not die and the limitations of currently available prostate screening tests has led to fluidity regarding the best prostate screening practices. As new data become available, the guidelines from major organizations seem to be increasingly similar with some nuances.
++
The USPSTF recommends against prostate cancer screening (recommendation D), based on their conclusion of the current evidence that there is very small potential benefit and significant potential risk from screening. The American Academy of Family Physicians (AAFP) supports the USPSTF guidelines.
++
The American Cancer Society (ACS) recommends that men make an informed decision with their physicians as to whether they should be tested for prostate cancer. Starting at age 50 years, men should discuss the pros and cons of testing with a physician. If they are African American or have a father or brother who had prostate cancer before age 65, men should discuss testing with a physician starting at age 45. If men decide to be tested, they should opt for the prostate-specific antigen (PSA) blood test with or without a rectal exam. How often they are tested will depend on their PSA level.
++
The American Urologic Association (AUA) guidelines are as follows:
++
PSA screening in men under age 40 years is not recommended.
Routine screening in men aged 40–54 years at average risk is not recommended.
For men aged 55–69 years, the decision to undergo PSA screening involves weighing the benefits of preventing prostate cancer mortality in 1 man for every 1000 men screened over a decade against the known potential risks associated with screening and treatment. For this reason, shared decision making is recommended for men aged 55–69 years who are considering PSA screening, and proceeding according to patients’ values and preferences.
To reduce the harms of screening, a routine screening interval of ≥2 years may be preferred over annual screening in those men who have participated in shared decision making and decided on screening. As compared to annual screening, it is expected that 2-year screening intervals will preserve most of the benefits and reduce the risk of overdiagnosis and false positives.
Routine PSA screening is not recommended in men over age 70 or any man with a <10–15-year life expectancy.
++
The reasons for these changes away from the prior recommendations to screen are based on new, large, long-running studies. Also, epidemiologic data factor in as well. Prostate cancer is the most common nondermatologic cancer in US males. If they live to be 90 years old, one out of six US males will be diagnosed with prostate cancer. Risk factors for development of prostate cancer include advanced age, family history, and race. Nearly 70% of prostate cancer diagnoses occur in men aged ≥65 years. The risk of developing prostate cancer is nearly 2.5 times greater in men with a family history of prostate cancer in a first-degree relative. Rates of prostate cancer occurrence are lower in Asian and Hispanic males than in non-Hispanic Caucasian males. African-American men are at twice the risk of white men. While US men have an approximately 16% lifetime risk of being diagnosed with prostate cancer, they have only ~3% risk of dying from it.
++
Digital rectal examination (DRE) and prostate-specific antigen (PSA) testing are the most commonly used prostate cancer screening tools. Physician-performed DRE is limited in that it allows only a portion of the prostate gland to be palpated and has poor interrater reliability. Sensitivity of DRE is low (53–59%), and positive predictive value (PPV) is only 18–28%. The PPV of PSA for prostate cancer screening is similarly low, at ~30%. Proposed prostate cancer screening methods include using PSA cutoff of 4 ng/mL, measuring PSA velocity, and percent free PSA. No currently available data demonstrates a mortality benefit with any of these. Whether DRE adds value to PSA screening is debatable, if not doubtful. DRE should not be used as a standalone test to screen for prostate cancer.
++
Both DRE and PSA screening can lead to detection of clinically insignificant prostate cancers, exposing patients to undue psychological distress and potentially harmful procedures and treatments, such as biopsy and radical prostatectomy. Unfortunately, DRE and PSA screening can also miss aggressive prostate cancers.
+++
5. Lung cancer screening
++
The USPSTF assigns a B recommendation to annual screening for lung cancer with low-dose computed tomography in adults aged 55–80 years who have a 30-pack/yr smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to undergo curative lung surgery. This has been a controversial recommendation because of concerns about radiation exposure (high false positive findings on initial screen leading to more CT scanning; the 25-year recommendation is based on studies of 3 years of screening), cost-benefit concerns, and the unsure role of screening in people who continue to smoke (eg, whether a negative screen will impede the desire to quit, whether a false-positive screen will result in increased quit rates). The AAFP has not endorsed this recommendation. Like all USPSTF recommendations, it will be reevaluated as new data emerge.
+++
G. Health Maintenance: Ages 60–74
++
Table 15-12 summarizes USPSTF recommendations for average-risk 60–74-year-olds.
++
++
Screening tests in focus: Abdominal aortic aneurysm (AAA) and osteoporosis.
+++
1. Screening for abdominal aortic aneurysm (AAA), men only:
++
One-time screening for AAA by ultrasonography in men aged 65–75 who have ever smoked (B).
No recommendation for or against screening for AAA in men aged 65–75 years who have never smoked (C).
Against routine screening for AAA in women (D), due to false-positive rate and lower prevalence of AAA.
+++
2. Screening for osteoporosis in postmenopausal women:
++
All women aged ≥65 years should be screened routinely for osteoporosis (B).
Women at increased risk1 for osteoporotic fractures should begin screening at age 60 (B).
No recommendation for or against routine osteoporosis screening in postmenopausal women aged <60 or in women aged 60–64 years who are not at increased risk for osteoporotic fractures (C).
++
Screening should occur every 3 years even if treatment is initiated.
+++
Osteoporosis Risk Assessment Tools
++
+
Cadarette
SM, Jaglal
SB, Kreiger
N, McIsaac
WJ, Darlington
GA, Tu
JV Can Med Assoc J. 2000;162(9):1289–1294.
+++
H. Health Maintenance: Age ≥75
++
Perhaps the most important aspect of health maintenance in people aged ≥75 years is lifestyle. HM recommendations for this age group are summarized in Table 15-13 and discussed below.
++
++
In patients aged ≥75 years, health maintenance decisions become more complex. The focus remains both primary and secondary prevention; however, there are relatively few studies evaluating the utility and impact of HM interventions in this population. Therefore, it becomes increasingly important to work with geriatric patients to make informed, individualized HM decisions. Among patients aged ≥75 years, there exist wide variations in the number and severity of comorbid conditions, functional status, life expectancy, and patients’ overall goals of care and preferences. Each of these factors must be considered when discussing HM interventions in older patients. Consideration of both benefits and risks of any HM intervention is also essential.
++
Guidelines regarding cancer screening in patients aged ≥75 years especially require individualized, patient-specific discussions and decisions. The United States Preventive Task Force (USPSTF) suggests that the benefits of colon cancer screening in adults aged 75–85 years do not outweigh the risks, and explicitly recommends against it in patients aged >85 years. The American College for Gastroenterology (ACG) recommends colon cancer screening beginning at age 50 and does not suggest when to discontinue screening.
++
For breast cancer screening, USPSTF recommends neither for nor against mammography in women aged ≥75 years. The American Geriatric Society (AGS) recommends screening mammography every 3 years after age 75 with no upper age limit for women with an estimated life expectancy of ≥4 years. The American Cancer Society (ACS) and USPSTF agree that older women with previously negative Pap results do not benefit from ongoing screening for cervical cancer after the age of 75.
++
Prostate cancer screening remains a controversial topic, with USPSTF advising against the use of prostate-specific antigen (PSA) for prostate cancer. A detailed discussion of prostate cancer and prostate cancer screening is included elsewhere in this chapter.
++
The American Geriatric Society recommends screening all older adults for a history of falls within the last year, and USPSTF recommends the use of exercise, physical therapy, and vitamin D supplementation in community-dwelling older adults at increased risk for falls. USPSTF recommends neither for nor against screening for vision impairment, hearing impairment or dementia in asymptomatic patients aged ≥75 years.
+++
I. Health Maintenance: Adult Immunizations
++
Tables 15-14 and 15-15 summarize the vaccination recommendations for adults.
++
++
+
American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119:e391–497.
+
Becker
R
et al.. The primary and secondary prevention of coronary artery disease. Chest. 2008;133;S776–S814.
+
Bhatt
DL
et al.. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118;1894–1909.
+
Buse
JB
et al.. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Assocation. Circulation. 2007;115:114–126.
+
Catalona
WJ
et al.. Comparison of digitial rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;11:1283–1290.
+
De Berardis
G
et al..
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomized controlled trials.
Br Med J. 2009;339:b4531.
+
Jemal
A
et al.. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.
+
Lanza
FL, Chan
FK, Quigley
EM, and the Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2009;104:728–738.
+
Lefevre
M Prostate cancer screening: let patients decide. Am Fam Physician. 2008:78(12):1388–1389.
+
Lim
L
et al.. Screening for prostate cancer in U.S. men; ACPM position statement on preventive practice. Am J Prevent Med. 2008; 34(2):164–170.
+
Lin
K
et al.. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192–199.
+
Miller
AB, Baines
CJ, To
T, Wall
C Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J. 1992; 147:1459–1476.
+
Mistry
K, Cable
G Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Practice. 2003;16(2):95–101.
+
Rex
DK, Johnson
DA, Anderson
JC
et al.. American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008. Am J Gastroenterol. 2009;104(3):739–750.
+
Ross
A, Clark
M Cancer screening in the older adult. Am Fam Physician. 2008;78(12):1369–1374.
+
Salem
D, O’Gara
P, Madias
C Valvular and structural heart disease. Chest. 2008;133;S593–S629.
+
Saslow
D
et al.. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. CA Cancer J Clin. 2002;52:342–362.
+
Smith
DS, Catalona
WJ Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology. 1995;45(1):689–697.
+
Smith
R
et al.. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009; 59:27–41.
+
Spalding,
M, Sebesta
S Geriatric screening and preventive care. Am Fam Physician. 2008; 78(2):206–215.
+
Takahashi
P
et al.. Preventive health care in the elderly population: a guide for practicing physicians. Mayo Clin Proc. 2004; 79:416–427.
+
Terret
C
et al.. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol. 2009; 10:80–87.
+
United States Preventive Services Task Force. Guide to Clinical Preventive Services, Recommendations for Adults (accessed Feb. 24, 2014).